| Overview |
| bs-11324R-Cy5 |
| NOVA1 Polyclonal Antibody, Cy5 Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Cow, Chicken |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human NOVA1 |
| 411-510/510 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| P51513 |
| Nucleus |
| Neuro oncological ventral antigen 1; Neuro-oncological ventral antigen 1; NOVA 1; Nova-1; Nova1; NOVA1_HUMAN; Onconeural ventral antigen 1; Paraneoplastic Ri antigen; RNA binding protein Nova 1; RNA-binding protein Nova-1; Ventral neuron specic protein 1; Ventral neuron-specic protein 1. |
| Nova-1 and Nova-2 are members of a superfamily of protein regulators of RNA metabolism in neurons. Both are nuclear RNA binding proteins with K homology motifs, conserved protein sequences which bind to RNA (1,2). Nova proteins, normally sequestered in the central nervous system, are expressed by systemic tumors in patients with the autoimmune disorder paraneoplastic opsoclonus-myoclonus ataxia (POMA) (3,4). Nova-1 is expressed in the hindbrain and ventral spinal cord and Nova-2 is expressed in the neocortex and hippocampus (4). Nova-1 is necessary for regulating neuron-specific alternative splicing of the glycine receptor Alpha2 pre-mRNA (5). |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz